Largest microRNA Therapeutics Alliance To Date

Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

Carlsbad, CA., June 22, 2010 – Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics.  The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.  The alliance will initially focus on the therapeutic area of fibrosis.  Regulus and sanofi-aventis will collaborate on up to four microRNA targets, including Regulus’ lead fibrosis program targeting microRNA-21.  sanofi-aventis also receives an option for a broader technology alliance that provides Regulus certain rights to participate in development and commercialization of resulting products.  If exercised, this three-year option is worth an additional $50 million to Regulus. (read more… )

Subscribe to the miRNA blog

Thank you for subscribing.

Something went wrong.

Related Posts

Add Comment